

## **Additional file 5**

**Table S4.** Multivariate Analysis for Heart V10 and Overall Survival

Variables	HR	95% CI	P value
Model <b>Heart V10/ Mean lung dose</b>	Body mass index (kg/m <sup>2</sup> ) ( $\leq 21.3$ vs. $> 21.3$ )	1.744	0.890-3.417
	Body surface area (m <sup>2</sup> ) ( $\leq 1.65$ vs. $> 1.65$ )	1.155	0.580-2.299
	ECOG performance status (0–1 vs. 2–3)	0.240	0.120-0.479
	Stage (I&II vs. III)	0.029	0.004-0.209
	Chemotherapy regimen (F vs. NF)	0.165	0.064-0.429
	Heart volume (ml) ( $\leq 592$ vs. $> 592$ )	0.720	0.436-1.188
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.996-0.999
	PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.005
<b>Heart V10 (%) (continuous)</b>		1.010	1.001-1.019
<b>Mean lung dose (cGy) (continuous)</b>		1.001	1.000-1.002
Model <b>Heart V10/ Lung V5</b>	Body mass index (kg/m <sup>2</sup> ) ( $\leq 21.3$ vs. $> 21.3$ )	1.545	0.798-2.990
	Body surface area (m <sup>2</sup> ) ( $\leq 1.65$ vs. $> 1.65$ )	1.410	0.729-2.726
	ECOG performance status (0–1 vs. 2–3)	0.271	0.139-0.532
	Stage (I&II vs. III)	0.051	0.008-0.310
	Chemotherapy regimen (F vs. NF)	0.217	0.088-0.538
	Heart volume (ml) ( $\leq 592$ vs. $> 592$ )	0.757	0.459-1.248
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.997-1.000
	PTV prescribed to 50 Gy (ml) (continuous)	1.002	1.001-1.004
<b>Heart V10 (%) (continuous)</b>		1.010	1.001-1.020
<b>Lung V5 (%) (continuous)</b>		1.015	0.988-1.043
Model <b>Heart V10/ Lung V10</b>	Body mass index (kg/m <sup>2</sup> ) ( $\leq 21.3$ vs. $> 21.3$ )	1.506	0.781-2.903
	Body surface area (m <sup>2</sup> ) ( $\leq 1.65$ vs. $> 1.65$ )	1.407	0.728-2.719
	ECOG performance status (0–1 vs. 2–3)	0.262	0.133-0.517
	Stage (I&II vs. III)	0.050	0.008-0.304
	Chemotherapy regimen (F vs. NF)	0.219	0.088-0.546
	Heart volume (ml) ( $\leq 592$ vs. $> 592$ )	0.747	0.450-1.238
	PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.997-1.000
	PTV prescribed to 50 Gy (ml) (continuous)	1.002	1.001-1.004
<b>Heart V10 (%) (continuous)</b>		1.011	1.002-1.020
<b>Lung V10 (%) (continuous)</b>		1.016	0.979-1.055

<b>Model</b>	<b>Heart V10/ Lung V20</b>	Body mass index ( $\text{kg}/\text{m}^2$ ) ( $\leq 21.3$ vs. $> 21.3$ )	1.498	0.780-2.877	0.225
		Body surface area ( $\text{m}^2$ ) ( $\leq 1.65$ vs. $> 1.65$ )	1.335	0.688-2.588	0.393
		ECOG performance status (0–1 vs. 2–3)	0.237	0.117-0.481	0.000
		Stage (I&II vs. III)	0.044	0.007-0.277	0.001
		Chemotherapy regimen (F vs. NF)	0.207	0.082-0.521	0.001
		Heart volume (ml) ( $\leq 592$ vs. $> 592$ )	0.713	0.426-1.191	0.196
		PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.996-1.000	0.017
		PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.004	0.003
		<b>Heart V10 (%) (continuous)</b>	1.011	1.002-1.020	0.020
		<b>Lung V20 (%) (continuous)</b>	1.036	0.983-1.092	0.191
<b>Model</b>	<b>Heart V10/ Lung V30</b>	Body mass index ( $\text{kg}/\text{m}^2$ ) ( $\leq 21.3$ vs. $> 21.3$ )	1.515	0.787-2.918	0.214
		Body surface area ( $\text{m}^2$ ) ( $\leq 1.65$ vs. $> 1.65$ )	1.332	0.684-2.591	0.399
		ECOG performance status (0–1 vs. 2–3)	0.236	0.116-0.478	0.000
		Stage (I&II vs. III)	0.043	0.007-0.269	0.001
		Chemotherapy regimen (F vs. NF)	0.219	0.088-0.540	0.001
		Heart volume (ml) ( $\leq 592$ vs. $> 592$ )	0.698	0.415-1.173	0.175
		PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.996-1.000	0.016
		PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.004	0.002
		<b>Heart V10 (%) (continuous)</b>	1.011	1.003-1.020	0.012
		<b>Lung V30 (%) (continuous)</b>	1.044	0.981-1.110	0.178
<b>Model</b>	<b>Heart V10/ Lung V40</b>	Body mass index ( $\text{kg}/\text{m}^2$ ) ( $\leq 21.3$ vs. $> 21.3$ )	1.491	0.772-2.879	0.235
		Body surface area ( $\text{m}^2$ ) ( $\leq 1.65$ vs. $> 1.65$ )	1.376	0.709-2.671	0.345
		ECOG performance status (0–1 vs. 2–3)	0.248	0.124-0.494	0.000
		Stage (I&II vs. III)	0.044	0.007-0.272	0.001
		Chemotherapy regimen (F vs. NF)	0.238	0.097-0.579	0.002
		Heart volume (ml) ( $\leq 592$ vs. $> 592$ )	0.706	0.419-1.191	0.192
		PTV prescribed to 36 Gy (ml) (continuous)	0.998	0.996-1.000	0.021
		PTV prescribed to 50 Gy (ml) (continuous)	1.003	1.001-1.004	0.003
		<b>Heart V10 (%) (continuous)</b>	1.012	1.003-1.021	0.010
		<b>Lung V40 (%) (continuous)</b>	1.044	0.972-1.121	0.236

Abbreviations: *ECOG* Eastern Cooperative Oncology Group, *F* fluoropyrimidine-based, *NF* not fluoropyrimidine-based, *PTV* planning target volume, *Vx* percentage of the heart volume receiving more than x gray